Abstract
Tubular cell loss is prominent both in acute and chronic renal failure. Apoptosis and its regulatory mechanisms contribute to cell number regulation in the kidney. The potential role of apoptosis ranges from induction and progression to repair of renal injury. However, therapeutic interest has focused in preventing the apoptotic loss of tubular cells that leads to acute and chronic renal failure. Death ligands and receptors, such as tumor necrosis factor and Fas ligand, proapoptotic and antiapoptotic Bcl2 family members and caspases have all been shown to participate in apoptosis regulation in the course of renal cell injury. Nevertheless, the precise role of these proteins is unclear, and the participation of most known apoptosis regulatory proteins has not been studied. We now review the role of apoptosis in renal injury, the potential molecular targets of therapeutic intervention, the therapeutic weapons to modulate the activity of these targets and the few examples of therapeutic intervention on apoptosis, with emphasis in acute renal failure.
Keywords: Apoptosis, kidney, acute renal failure, Bcl2, death receptor, caspase
Current Medicinal Chemistry
Title: Modulation of Renal Tubular Cell Survival: Where is the Evidence?
Volume: 13 Issue: 4
Author(s): C. Lorz, A. Benito-Martin, P. Justo, A. B. Sanz, M. D. Sanchez-Nino, B. Santamaria, J. Egido and A. Ortiz
Affiliation:
Keywords: Apoptosis, kidney, acute renal failure, Bcl2, death receptor, caspase
Abstract: Tubular cell loss is prominent both in acute and chronic renal failure. Apoptosis and its regulatory mechanisms contribute to cell number regulation in the kidney. The potential role of apoptosis ranges from induction and progression to repair of renal injury. However, therapeutic interest has focused in preventing the apoptotic loss of tubular cells that leads to acute and chronic renal failure. Death ligands and receptors, such as tumor necrosis factor and Fas ligand, proapoptotic and antiapoptotic Bcl2 family members and caspases have all been shown to participate in apoptosis regulation in the course of renal cell injury. Nevertheless, the precise role of these proteins is unclear, and the participation of most known apoptosis regulatory proteins has not been studied. We now review the role of apoptosis in renal injury, the potential molecular targets of therapeutic intervention, the therapeutic weapons to modulate the activity of these targets and the few examples of therapeutic intervention on apoptosis, with emphasis in acute renal failure.
Export Options
About this article
Cite this article as:
Lorz C., Benito-Martin A., Justo P., Sanz B. A., Sanchez-Nino D. M., Santamaria B., Egido J. and Ortiz A., Modulation of Renal Tubular Cell Survival: Where is the Evidence?, Current Medicinal Chemistry 2006; 13 (4) . https://dx.doi.org/10.2174/092986706775527956
DOI https://dx.doi.org/10.2174/092986706775527956 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Aptamers as Targeting Delivery Devices or Anti-cancer Drugs for Fighting Tumors
Current Drug Metabolism Molecular Structural Characteristics of Estrogen Receptor Modulators as Determinants of Estrogen Receptor Selectivity
Mini-Reviews in Medicinal Chemistry DNA Methylation, An Epigenetic Mode of Gene Expression Regulation in Reproductive Science
Current Pharmaceutical Design Nanostructured Lipid Carriers (NLCs) for Drug Delivery: Role of Liquid Lipid (Oil)
Current Drug Delivery Emerging Role of Wnt/Beta-Catenin Signalling Pathways in Cancer Progression and Role of Small Molecule Tankyrase Inhibitors in Combating Multistage Cancers
Current Cancer Therapy Reviews IGF-I Abuse in Sport
Current Drug Abuse Reviews Healthcare Management During A Pandemic: The Other Side of the Coin for the Treatment of COVID-19 Infection
Endocrine, Metabolic & Immune Disorders - Drug Targets Hypothyroidism and Nephrotic Syndrome: Why, When and How to Treat
Current Vascular Pharmacology Growth Restriction: Etiology, Maternal and Neonatal Outcome. A Review
Current Women`s Health Reviews Smoking and Hypertension: Independent or Additive Effects to Determining Vascular Damage?
Current Vascular Pharmacology Dual-Targeted Molecular Probes for Cancer Imaging
Current Pharmaceutical Biotechnology Progress on the Screening and Analysis of Bioactive Compounds in Traditional Chinese Medicines by Biological Fingerprinting Analysis
Combinatorial Chemistry & High Throughput Screening Signaling Processes in Tumoral Neuroendocrine Pituitary Cells as Potential Targets for Therapeutic Drugs
Current Drug Targets - Immune, Endocrine & Metabolic Disorders In Silico Modeling of Crabtree Effect
Endocrine, Metabolic & Immune Disorders - Drug Targets Editorial: Recent developments in the Application of Separation and Hyphenated Techniques in Current Diagnostic Challenges
Current Medicinal Chemistry Targeting ADAM12 in Human Disease: Head, Body or Tail?
Current Pharmaceutical Design Significance of and Challenges in Regulating Endocrine Disruptors – How Regulators and Industry Can Conquer?
Endocrine, Metabolic & Immune Disorders - Drug Targets Subject Index to Volume 2
Current Pharmacogenomics Treatment of ‘Diabesity’: Beyond Pharmacotherapy
Current Drug Targets HER-2 Signaling and Inhibition in Breast Cancer
Current Cancer Drug Targets